ArticleCancer genomics & proteomics
MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy.
Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Pooled it
- Diagnostic and Prognostic Value of MicroRNAs in Metastasis and Recurrence of Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Exploring CSF microRNA signatures as diagnostic biomarkers in adult-type diffuse gliomas.Non-coding RNA research · 2026Article
- Decoding the role of non-coding RNAs in HNSCC radioresistance: molecular mechanisms and clinical implications.Frontiers in oncology · 2026Review
- Article
- The Potential microRNA Prognostic Signature in HNSCCs: A Systematic Review.Non-coding RNA · 2023Review
- Network approach in liquidomics landscape.Journal of experimental & clinical cancer research : CR · 2023Review
- RNA-Based Liquid Biopsy in Head and Neck Cancer.Cells · 2023Review
- Pharmacological impact of microRNAs in head and neck squamous cell carcinoma: Prevailing insights on molecular pathways, diagnosis, and nanomedicine treatment.Frontiers in pharmacology · 2023Review
- Saliva Based Liquid Biopsies in Head and Neck Cancer: How Far Are We From the Clinic?Frontiers in oncology · 2022Review
- A Comprehensive Review on Function of miR-15b-5p in Malignant and Non-Malignant Disorders.Frontiers in oncology · 2022Review
- Dynamic Characteristics and Predictive Capability of Tumor Voxel Dose-Response Assessed UsingFrontiers in oncology · 2022Article
- Article
- MicroRNA: a novel implication for damage and protection against ionizing radiation.Environmental science and pollution research international · 2021Review
- Review
- MicroRNA‑15b‑5p exerts its tumor repressive role via targeting GDI2: A novel insight into the pathogenesis of thyroid carcinoma.Molecular medicine reports · 2020Article
- Salivary microRNAs identified by small RNA sequencing as potential predictors of response to intensity-modulated radiotherapy in head and neck cancer patients.Cellular oncology (Dordrecht, Netherlands) · 2020Article
- Insight toward the MicroRNA Profiling of Laryngeal Cancers: Biological Role and Clinical Impact.International journal of molecular sciences · 2020Review
- Inhibition of microRNA-15b-5p Attenuates the Progression of Oral Squamous Cell Carcinoma via Modulating theCancer management and research · 2020Article
- miR-221-3p and miR-15b-5p promote cell proliferation and invasion by targeting Axin2 in liver cancer.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimHead and neck cancers are a heterogenous group of epithelial tumors represented mainly by squamous cell carcinomas (HNSCC), which are the sixth most common type of cancer worldwide. Surgery together with radiotherapy (RT) is among the basic treatment modalities for most HNSCC patients. Various biomarkers aiming to predict patients' response to RT are currently investigated. The reason behind this effort is, on one hand, to distinguish radioresistant patients that show weak benefit from RT and, on the other hand, reduce the ionizing radiation dose in less aggressive radiosensitive HNSCC with possibly less acute or late toxicity. MATERIALS AND
methodsA total of 94 HNSCC patients treated by definitive intensity-modulated radiotherapy were included in our retrospective study. We used a global expression analysis of microRNAs (miRNAs) in 43 tumor samples and validated a series of selected miRNAs in an independent set of 51 tumors.
resultsWe identified miR-15b-5p to be differentially expressed between patients with short and long time of locoregional control (LRC). Kaplan-Meier analysis confirmed that HNSCC patients with higher expression of miR-15b-5p reach a significantly longer locoregional relapse-free survival compared to patients expressing low levels. Finally, multivariable Cox regression analysis revealed that miR-15b-5p is an independent predictive biomarker of LRC in HNSCC patients (HR=0.25; 95% CI=0.05-0.78; p<0.016).
conclusionmiR-15b-5p represents a potentially helpful biomarker for individualized treatment decisions concerning the management of HNSCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.